Ashish Kumar

This paper develops a gene therapy vector targeting KSHV-infected cells using AAV8-TR2-OriP-TK, which, when combined with ganciclovir, effectively eradicates KSHV-associated cancers in xenograft models.

This study investigates how KSHV terminal repeats (TR) function as enhancers by regulating BRD4 recruitment and promoter activation during viral reactivation.

This paper identifies KSHV terminal repeat (TR) as a regulatory domain that enhances lytic gene promoters through interactions with LANA and histone modifications.